Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.

被引：3
|
作者：
Powles, Thomas
Albiges, Laurence
Jalkanen, Katriina Johanna
De Velasco, Guillermo
Burotto, Mauricio
Ghatalia, Pooja
Suarez, Cristina
Lam, Elaine T.
Iacovelli, Roberto
Gumus, Mahmut
Verzoni, Elena
Kollmannsberger, Christian K.
Stadler, Walter Michael
Venugopal, Balaji
Shinde, Reshma
Saretsky, Todd L.
He, Li
Vickery, Donna
Choueiri, Toni K.
Rini, Brian I.
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, London, England
[2] Univ Paris Saclay, Gustave Roussy, Paris, France
[3] Helsinki Univ Hosp, Helsinki, Finland
[4] 12 Octubre Univ Hosp, Med Oncol Dept, Madrid, Spain
[5] Bradford Hill Clin Res Ctr, Santiago, Chile
[6] Fox Chase Canc Ctr, Philadelphia, PA USA
[7] Hosp Univ Vall dHebron, Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[8] Univ Colorado, Canc Ctr, Aurora, CO USA
[9] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy
[10] Istanbul Medeniyet Univ, Goztepe Prof Dr Suleyman Yalcin City Hosp, Istanbul, Turkiye
[11] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[12] BC Canc Vancouver Canc Ctr, Vancouver, BC, Canada
[13] Univ Chicago, Chicago, IL USA
[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Scotland
[15] Merck & Co Inc, Rahway, NJ USA
[16] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[17] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.361
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
361
引用
收藏
页码：361 / 361
页数：1
相关论文
共 50 条
  • [21] Evaluation of the novel "trial within a trial" design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)
    Hessel, C.
    Mangeshkar, M.
    Motzer, R. J.
    Escudier, B.
    Powles, T. B.
    Schwab, G.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
    Schmidinger, M.
    Tannir, N. M.
    Powles, T.
    Escudier, B. J.
    Donskov, F.
    Gruenwald, V
    Sternberg, C. N.
    Schoffski, P.
    Szczylik, C.
    Peltola, K. J.
    Nosov, D.
    Melichar, B.
    Clary, D. O.
    Scheffold, C.
    Motzer, R. J.
    Choueiri, T. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 200 - 200
  • [23] Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).
    Tannir, Nizar M.
    Powles, Thomas
    Escudier, Bernard J.
    Donskov, Frede
    Grunwald, Viktor
    Sternberg, Cora N.
    Schmidinger, Manuela
    Schoffski, Patrick
    Szczylik, Cezary
    Peltola, Katriina Johanna
    Nosov, Dmitry
    Melichar, Bohuslav
    Clary, Douglas O.
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)
    Mainwaring, Paul
    Tannir, Nizar M.
    Powles, Thomas
    Motzer, Robert J.
    Rolland, Frederic
    Gravis, Gwanaelle
    Staehler, Michael
    Rink, Michael
    Retz, Margitta
    Csoszi, Tibor
    McCaffrey, John A.
    De Giorgi, Ugo
    Caserta, Claudia
    Cheporov, Sergey
    Gonzalez, Emilio Esteban
    Duran, Ignacio
    Larkin, James G.
    Berg, William
    Clary, Douglas O.
    Escudier, Bernard
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 129 - 130
  • [25] EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES (PROS) WITH CRIZOTINIB VERSUS CHEMOTHERAPY IN ASIAN PATIENTS IN A PHASE III STUDY OF PREVIOUSLY TREATED ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Nishio, Makoto
    Hirsh, Vera
    Kim, Dong-Wan
    Wilner, Keith D.
    Polli, Anna
    Reisman, Arlene
    Iyer, Shrividya
    Blackhall, Fiona
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S198 - S199
  • [26] Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial
    Bourlon, Maria T.
    Albiges, Laurence
    Chacon, Matias Rodrigo
    Cutuli, Hernan
    Zurawski, Bogdan
    Mota, Jose Mauricio
    Magri, Ignacio
    Burotto, Mauricio
    Luz, Murilo
    Menezes, Juliana
    Ruiz, Eduardo Patricio Yanez
    Maruzzo, Marco
    Bracarda, Sergio
    Prusty, Subhransu
    Rathod, Dhanrajsinh
    Yu, Zhuoxin
    Gurm, Balmeet
    Dixon, Matthew
    George, Saby
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564
    Choueiri, T. K.
    Tomczak, P.
    Park, S. H.
    Venugopal, B.
    Symeonides, S.
    Hajek, J.
    Ferguson, T.
    Chang, Y-H.
    Lee, J. L.
    Haas, N.
    Sawrycki, P.
    Sarwar, N.
    Gross-Goupil, M.
    Thiery-Vuillemin, A.
    Mahave, M.
    Saretsky, T. L.
    Zhang, P.
    Willemann-Rogerio, J.
    Quinn, D. I.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S679 - S680
  • [28] Responder analysis based on patient-reported outcomes (PROs) and clinical endpoints (CEPs) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab
    D'Angelo, S. P.
    Fofana, F.
    Schlichting, M.
    Henry-Szatkowski, M.
    Hennessy, M.
    Bharmal, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
    Cella, D.
    Escudier, B.
    Rini, B. I.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J. C.
    Rosbrook, B.
    Kim, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
    Pal, Sumanta K.
    McDermott, David F.
    Atkins, Michael B.
    Escudier, Bernard
    Rini, Brian I.
    Motzer, Robert J.
    Fong, Lawrence
    Joseph, Richard W.
    Oudard, Stephane
    Ravaud, Alain
    Bracarda, Sergio
    Suarez, Cristina
    Lam, Elaine T.
    Choueiri, Toni K.
    Ding, Beiying
    Quach, Caroleen
    Hashimoto, Kenji
    Schiff, Christina
    Piault-Louis, Elisabeth
    Powles, Thomas
    BJU INTERNATIONAL, 2020, 126 (01) : 73 - 82
12345